L & S Advisors’s Cardlytics CDLX Stock Holding History

L & S Advisors’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-500	Closed	-$635K	–	342
2021 Q2	$635K	Buy	+500	New	+$564K	0.07%	229

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

L & S Advisors's CDLX Position: Q3 2021 in Review

L & S Advisors sold out of Cardlytics (CDLX) in Q3 2021, closing a stake of 500 shares — an estimated $635K sold.

L & S Advisors first reported a position in CDLX in Q2 2021 and held it in 1 quarter. The position peaked at $635K in Q2 2021. 164 funds tracked by Wall St. Rank hold CDLX as of Q3 2021.

L & S Advisors reported no remaining Cardlytics position as of Q3 2021 after selling out during the quarter.
L & S Advisors sold 500 Cardlytics shares in Q3 2021, an estimated $635K.
L & S Advisors first reported a position in Cardlytics in Q2 2021 and held it in 1 quarter.
L & S Advisors's Cardlytics position peaked at $635K in Q2 2021.
164 funds tracked by Wall St. Rank held Cardlytics as of Q3 2021.

Based on L & S Advisors's 13F filing for Q3 2021, filed 9 Nov 2021.